Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis, Study

Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

Treatment with the Australian company’s mesenchymal precursor cell (MPC) product, MPC-300-IV, was deemed well tolerated with no serious side effects or infusion-related adverse events in the 48-patient, 12-week Phase II study, the company said.

Among patients previously treated with at least one biologic drug, the common measure of 20 percent relief of signs and symptoms of the arthritis, known as ACR20, was achieved by 55 percent of those who received an infusion of 2 million cells per kilogram of weight. That compared with 33 percent in the placebo group who achieved ACR20.

The higher bar of ACR70, or 70 percent improvement, was achieved by 36 percent after one infusion of the Mesoblast treatment, compared with no patients in the placebo group who reported such an improvement… Read More>>

Source: Reuters

Send this to a friend